Advertisement
Screener

Oruka Therapeutics, Inc. (ORKA) Proceeds from Issuance of Redeemable Preferred Stock

1.6 / 5 stars · 15/47 Roast Me

Oruka Therapeutics, Inc. Proceeds from Issuance of Redeemable Preferred Stock

Oruka Therapeutics, Inc. (ORKA) reported Proceeds from Issuance of Redeemable Preferred Stock of $38.00 thousand for the 135-month period ending 2013-03-31, per its 10-Q filed 2013-05-13.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock · last filed 2013-05-13

  • Oruka Therapeutics, Inc. proceeds from issuance of redeemable preferred stock for the quarter ending 2013-03-31 was $0.00.
  • Oruka Therapeutics, Inc. proceeds from issuance of redeemable preferred stock for the quarter ending 2012-12-31 was $0.00.
  • Oruka Therapeutics, Inc. proceeds from issuance of redeemable preferred stock for the quarter ending 2012-09-30 was $0.00.
  • Oruka Therapeutics, Inc. proceeds from issuance of redeemable preferred stock for the quarter ending 2012-06-30 was $0.00.
Period endProceeds from Issuance of Redeemable Preferred Stock 3 monthProceeds from Issuance of Redeemable Preferred Stock 6 monthProceeds from Issuance of Redeemable Preferred Stock 9 monthProceeds from Issuance of Redeemable Preferred Stock 12 monthProceeds from Issuance of Redeemable Preferred Stock 117 monthProceeds from Issuance of Redeemable Preferred Stock 120 monthProceeds from Issuance of Redeemable Preferred Stock 123 monthProceeds from Issuance of Redeemable Preferred Stock 126 monthProceeds from Issuance of Redeemable Preferred Stock 129 monthProceeds from Issuance of Redeemable Preferred Stock 132 monthProceeds from Issuance of Redeemable Preferred Stock 135 month
2013-03-31$0.00
derived: 10-Q 135 month − 10-K 132 month · filed 2013-05-13
$0.00
derived: sum of 2 quarters · filed 2013-05-13
$0.00
derived: sum of 3 quarters · filed 2013-05-13
$0.00
derived: sum of 4 quarters · filed 2013-05-13
$38.00K
10-Q · filed 2013-05-13
2012-12-31$0.00
derived: 10-K 132 month − 10-Q 129 month · filed 2013-03-21
$0.00
derived: sum of 2 quarters · filed 2013-03-21
$0.00
derived: sum of 3 quarters · filed 2013-03-21
$0.00
derived: sum of 4 quarters · filed 2013-03-21
$38.00K
10-K · filed 2013-03-21
2012-09-30$0.00
derived: 10-Q 129 month − 10-Q 126 month · filed 2012-11-13
$0.00
derived: sum of 2 quarters · filed 2012-11-13
$0.00
derived: sum of 3 quarters · filed 2012-11-13
$0.00
derived: sum of 4 quarters · filed 2012-11-13
$38.00K
10-Q · filed 2012-11-13
2012-06-30$0.00
derived: 10-Q 126 month − 10-Q 123 month · filed 2012-08-13
$0.00
derived: sum of 2 quarters · filed 2012-08-13
$0.00
derived: sum of 3 quarters · filed 2012-08-13
$38.00K
10-Q · filed 2012-08-13
2012-03-31$0.00
derived: 10-Q 123 month − 10-K 120 month · filed 2012-05-14
$0.00
derived: sum of 2 quarters · filed 2012-05-14
$38.00K
10-Q · filed 2012-05-14
2011-12-31$0.00
derived: 10-K 120 month − 10-Q 117 month · filed 2012-03-27
$38.00K
10-K · filed 2012-03-27
2011-09-30$38.00K
10-Q · filed 2011-11-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
Erasca, Inc. (ERAS)United States$5.073B-19.96
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Liquidia Corp (LQDA)United States$6.347B51.23
Veradermics, Inc (MANE)United States$4.839B